Introduction to Retevmo (Selpercatinib) 80mg 

Retevmo (Selpercatinib) 80mg is a prescription medicine used for the treatment of certain types of cancers with RET (rearranged during transfection) gene alterations. It is commonly prescribed for non-small cell lung cancer (NSCLC), thyroid cancer, and other RET fusion-positive cancers.

SELPACTA 80mg is classified under Prescription Medicines, Oncology Medicines, Targeted Cancer Therapies, and Tyrosine Kinase Inhibitors (TKIs). It contains Selpercatinib, which works by specifically targeting RET gene mutations responsible for cancer growth.

In many countries, Retevmo is the original brand containing the same active ingredient Selpercatinib, offering similar therapeutic benefits when prescribed by a qualified healthcare professional.

What Is Retevmo (Selpercatinib)? 

Retevmo is the brand name for Selpercatinib, an oral targeted therapy used in oncology.

Selpercatinib belongs to a class of medicines known as RET Tyrosine Kinase Inhibitors. These medicines block abnormal signaling pathways that promote cancer cell growth.

Generic versions such as SELPACTA 80mg contain the same active compound and may be used depending on physician recommendation and availability.

Drug Class and Mechanism of Action 

Selpercatinib is classified as a targeted anticancer agent with kinase inhibition activity.

How Selpercatinib Works 

It works in several ways:

• Inhibits RET kinase activity
• Blocks cancer cell growth signals
• Slows tumor progression

Through these mechanisms, Selpercatinib helps control cancer development and spread.

How Retevmo Works in the Body 

Certain cancers are driven by mutations in the RET gene, leading to uncontrolled cell growth.

Key Actions of Selpercatinib 

• Targets RET gene alterations
• Inhibits tumor cell proliferation
• Reduces tumor size and spread

SELPACTA 80mg provides precision therapy for cancers with RET mutations.

Medical Uses of Retevmo (Selpercatinib) 80mg 

SELPACTA 80mg is used in specific cancer treatments.

Non-Small Cell Lung Cancer (NSCLC) 

Used in patients with RET fusion-positive NSCLC.

Potential Benefits 

• Targeted tumor reduction
• Improved progression-free survival
• Better treatment response

Thyroid Cancer 

Used for medullary thyroid cancer and RET-mutant thyroid cancers.

Potential Benefits 

• Slows disease progression
• Controls metastatic disease

Who Can Take Retevmo (Selpercatinib) 80mg? 

This medicine should be used under specialist oncology supervision.

Eligibility Criteria 

Patients may be prescribed SELPACTA if they:

• Have RET gene mutation-positive cancers
• Require targeted therapy
• Are evaluated through genetic testing

Who Should Avoid Retevmo (Selpercatinib) 80mg 

This medicine should NOT be used by:

• Patients with hypersensitivity to Selpercatinib
• Individuals with severe uncontrolled hypertension
• Pregnant or breastfeeding women (unless advised)

Retevmo (Selpercatinib) 80mg Dosage and Administration 

Standard Dosage Guidelines 

Typical dosage includes:

• SELPACTA 80mg taken twice daily
• Taken with or without food
• Follow oncologist instructions strictly

Dosage Adjustments 

Doctors may adjust dosage depending on:

• Liver function
• Side effects
• Treatment response

Side Effects of Retevmo (Selpercatinib) 80mg

Like all cancer medicines, Selpercatinib may cause side effects.

Common Side Effects 

• Dry mouth
• Diarrhea
• Fatigue
• Increased blood pressure

Serious Side Effects 

• Liver toxicity
• QT prolongation (heart rhythm issues)
• Severe hypertension

Patients should report symptoms like chest pain, dizziness, or jaundice immediately.

Storage:
Store below 25°C in a cool, dry place, away from light. Keep out of reach of children.

Frequently Asked Questions (FAQs) 

1. Is Retevmo safe for long-term use? 

Yes, under strict oncologist supervision.

2. Is SELPACTA 80mg chemotherapy? 

No. It is a targeted therapy.

3. How does SELPACTA work? 

It targets RET gene mutations in cancer cells.

4. Is genetic testing required? 

Yes, to confirm RET mutation before treatment.

5. Can it cure cancer? 

It helps control cancer but may not cure it.

6. Is SELPACTA the same as Retevmo? 

Yes. Both contain Selpercatinib.

7. Do I need a prescription for SELPACTA 80mg? 

Yes. It is a prescription-only oncology medicine.

Medical Disclaimer 

Disclaimer:
This content is for educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional before using this medication.